New and old biomarkers of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic liver disease around the world. Development of biomarkers for early HCC detection is a primary public health goal to decrease mortality. The ideal biomarkers should be highly sensitive and specific for surveillance of high-risk populations and early detection of HCC and also be able to predict therapeutic outcome and provide a prognosis on survival. Currently, the new biomarkers do not perform better than the conventional ones such as alpha-fetoprotein in such a way that they could be widely adopted in clinical practice. Another problem is the low sensitivity of these biomarkers in the detection of HCC. Further work on the development of novel biomarkers and on a combination of them is necessary. Advances in identifying unique molecular signatures including genomic, proteomic, metabolomic, and glycomic profiles have improved our understanding of many biological processes involved in HCC. This review focuses on the role of old and new biomarkers in surveillance, diagnosis, prognosis, and prediction of response to therapeutic targets for HCC and provides up-to-date data to health-care providers which would be applied in clinical practice.

Keywords

Hepatocellular carcinoma / biomarkers / diagnosis / surveillance / prognosis / treatment response

References

[1] Collaboration Global Burden of Disease Liver Cancer,Abera S,Alam N.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[2] Soerjomataram I,Parkin DM,Mathers C.Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.Lancet2012;380:1840-50

[3] Parkin DM.The global health burden of infection-associated cancers in the year 2002.Int J Cancer2006;118:3030-44

[4] Makarova-Rusher OV,McNeel TS,Duffy AG.Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.Cancer2016;122:1757-65 PMCID:PMC5548177

[5] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors.Gastroenterology2004;127:S35-50

[6] Kanwal F,Kramer JR,Goetz MB.Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection.Gastroenterology2011;140:1182-8 PMCID:PMC3073667

[7] El-Serag HB.Hepatocellular Carcinoma.N Engl J Med2011;365:1118-27

[8] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004;130:417-22

[9] Chaiteerakij R,Addissie BD,Harmsen WS.Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.Liver Transpl2015;21:559-606 PMCID:PMC4490162

[10] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol2018;19:940-52

[11] Umeda S,Kodera Y.Emerging evidence of molecular biomarkers in hepatocellular carcinoma.Histol Histopathol2018;33:343-55

[12] Khan FS,Afridi UK,Mehmood R.Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.Hepatol Int2017;11:45-53

[13] Di Costanzo A,Migliaccio A.Epigenetic drugs against cancer: an evolving landscape.Arch Toxicol2014;88:1651-68

[14] Dhanak D.Development and classes of epigenetic drugs for cancer.Biochem Biophys Res Commun2014;455:58-69

[15] Pathil A,Venturelli S,Weiss TS.HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.Hepatology2006;43:425-34

[16] Yeo W,Chan SL,Lim R.Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase i/ii study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.J Clin Oncol2012;30:3361-7 PMCID:PMC3438233

[17] Terentiev AA.Alpha-fetoprotein: a renaissance.Tumor Biol2013;34:2075-91

[18] Peterson ML,Spear BT.Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer.Semin Cancer Biol2011;21:21-7 PMCID:PMC3313486

[19] Grizzi F,Taverna G,Cobos E.Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies?.Appl Immunohistochem Mol Morphol2007;15:134-9

[20] Gonzalez SA.Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?.Hepatobiliary Surg Nutr2014;3:410-4 PMCID:PMC4273110

[21] Schütte K,Link A.Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction of prognosis.World J Hepatol2015;7:139-49 PMCID:PMC4342597

[22] Tsukuma H,Tanaka S,Yabuuchi T.Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med1993;328:1797-1801

[23] McMahon BJ,Harpster A,Lanier A.Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study.Hepatology2000;32:842-6

[24] Di Bisceglie AM,Chung RT,Dienstag JL.Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial.J Hepatol2005;43:434-41

[25] Bruix J.Management of hepatocellular carcinoma: an update.Hepatology2011;53:1020-2 PMCID:PMC3084991

[26] Yamashita T,Forgues M.Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.Cancer Res2007;67:10831-9

[27] Villanueva A,Forner A,Llovet JM.Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.Annu Rev Med2010;61:317-28 PMCID:PMC3677155

[28] Hoshida Y,Kobayashi M,Brunet JP.Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.Cancer Res2009;69:7385-92 PMCID:PMC3549578

[29] Tao LY,He XD,Qu Q.Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Am Surg2010;76:1210-3

[30] Rimola J,Reig M,de Lope CR.Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.Hepatology2009;50:791-8

[31] Cancer European Organisation For Research And Treatment Of.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[32] Heimbach JK,Finn RS,Abecassis MM.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[33] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[34] Li C,Zhang XY,Wen TF.Predictors of futile liver resection for patients with Barcelona clinic liver cancer stage B/C hepatocellular carcinoma.J Gastrointest Surg2018;22:496-502

[35] Mazzaferro V,Zhou J,De Carlis L.Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma..Gastroenterology2018;154:128-39

[36] Sangiovanni A,Fasani P,Ronchi G.Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance.Gastroenterology2004;126:1005-14

[37] Pontisso P,Caberlotto C,Marino M.Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma.Int J cancer2006;119:735-40

[38] Kinoshita A,Fushiya N,Nishino H.Staging systems for hepatocellular carcinoma: current status and future perspectives.World J Hepatol2015;7:406-24 PMCID:PMC4381166

[39] Liu L,Jia J,Bai W.The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization.Sci Rep2016;doi:10

[40] Personeni N,Pressiani T,Tronconi MC.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.J Hepatol2012;57:101-7

[41] Nakazawa T,Takada J,Tanaka Y.Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.Eur J Gastroenterol Hepatol2013;25:683-9

[42] Tsuchiya N,Endo I,Uemura Y.Biomarkers for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol2015;21:10573-83 PMCID:PMC4588079

[43] Marrero JA,Wei W,Conjeevaram HS.Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients.Hepatology2003;37:1114-21

[44] Kumada T,Tada T,Tanikawa M.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma.J Gastroenterol2014;49:555-63 PMCID:PMC3953543

[45] Koike Y,Sato S,Teratani T.Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.Cancer2001;91:561-9

[46] Sterling RK,Gordon F,Venook AP.Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis.Am J Gastroenterol2007;102:2196-205

[47] Grizzi F,Hamrick C,Cobos E.Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.J Transl Med2007;5:3 PMCID:PMC1797003

[48] Zhang D,Yin X,Lu B.Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysis.Int J Biol Markers2018;33:266-74

[49] Marrero JA,Wang Y,Befeler AS,Reddy KR,Llovet JM,Dalhgren J,Lok AS,Srivastava S.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.Gastroenterology2009;137:110-8 PMCID:PMC2704256

[50] Lok AS,Everhart JE,Hoefs JC.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Gastroenterology2010;138:493-502 PMCID:PMC2819612

[51] Liu Z,Yang J.Upregulated and downregulated proteins in hepatocellular carcinoma: a systematic review of proteomic profiling studies.OMICS2011;15:61-71

[52] Budhu A,Zhao X,Forgues M.Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes.Gastroenterology2013;144:1066-75 PMCID:PMC3633738

[53] Beyoğlu D,Maurhofer O,Zucman-Rossi J.Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.Hepatology2013;58:229-38 PMCID:PMC3695036

[54] Fitian AI,Liu C,Ararat M.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.Liver Int2014;34:1428-44 PMCID:PMC4169337

[55] Ruhaak LR,Lebrilla CB.Developments in the identification of glycan biomarkers for the detection of cancer.Mol Cell Proteomics2013;12:846-55 PMCID:PMC3617331

[56] Chen K,Xin Z,Zhu X.Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci in a chinese population.PLoS One2013;

[57] Hippo Y,Watanabe A,Yamamoto S.Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.Cancer Res2004;64:2418-23

[58] Xu C,Zhou L.A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.J Cancer Res Clin Oncol2013;139:1417-24

[59] Tomimaru Y,Nagano H,Kobayashi S.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma.J Hepatol2012;56:167-75

[60] Chuma M,Yamazaki K,Ohki M.Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma.Hepatology2003;37:198-207

[61] Osada T,Nagawa H,Matsuno Y.Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis.Cancer1999;85:819-31

[62] Feng J,Chang C,Cao F.CK19 and glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection.PLoS One2016;

[63] Sun DW,Sun XD,Qiu W.Prognostic value of cytokeratin 19 in hepatocellular carcinoma: a meta-analysis.Clin Chim Acta2015;448:161-9

[64] Lee JI,Kim JM,Chung HJ.Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.World J Gastroenterol2012;18:4751-7 PMCID:PMC3442214

[65] Marrero JA,Nikolaeva O,Mehta A.GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.J Hepatol2005;43:1007-12

[66] Tian L,Xu D,Jia X.Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases.Int J Cancer2011;129:1923-31

[67] Xu WJ,Han YG,Ma WS.Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels.Tumor Biol2014;35:12069-74

[68] Qin L.Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.Front Med2014;8:24-32

[69] Ramchandani D.Interactions between osteopontin and vascular endothelial growth factor: implications for cancer.Biochim Biophys Acta2015;1855:202-22

[70] Shang S,Ge S,Rosen HR.Identification of osteopontin as a novel marker for early hepatocellular carcinoma.Hepatology2012;55:483-90 PMCID:PMC3914762

[71] Weber GF.The cancer biomarker osteopontin: combination with other markers.Cancer Genomics and Proteomics2011;8:263-88

[72] Giannelli G,Sgarra C,Dentico P.Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma.Int J Cancer2005;116:579-83

[73] Pozzan C,Piciocchi M,Maddalo G.Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC).J Gastroenterol Hepatol2014;29:1637-44

[74] Lokman NA,Oehler MK.The role of annexin A2 in tumorigenesis and cancer progression.Cancer Microenviron2011;4:199-208 PMCID:PMC3170418

[75] Sun Y,Cai J,Qu X.Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.Carcinogenesis2013;34:595-604 PMCID:PMC3581600

[76] Fu LL,Bao JK.MicroRNA-modulated autophagic signaling networks in cancer.Int J Biochem Cell Biol2012;44:733-6

[77] Morishita A.miRNA in hepatocellular carcinoma.Hepatol Res2015;45:128-41

[78] Borel F,Jansen PL.Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma.J Hepatol2012;56:1371-83

[79] Chen X,Ma W,Hong Z.The abnormal expression of microRNA-542-3p in hepatocellular carcinoma and its clinical significance.Dis Markers2018;

[80] Wong CC,Tung EK,Lee JM.The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2.Gastroenterology2011;140:322-31

[81] Sato F,Kitamura K,Fujiwara T.MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria.PLoS One2011;

[82] Mei Y,Xia J,Wang YB.Identifying differentially expressed microRNAs between cirrhotic and non-cirrhotic hepatocellular carcinoma and exploring their functions using bioinformatic analysis.Cell Physiol Biochem2018;48:1443-56

[83] Wang H,Dong Q,He J.Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma.Theranostics2018;8:2814-29 PMCID:PMC5957011

[84] Carninci P,Katayama S,Frith MC.The transcriptional landscape of the mammalian genome.Science2005;309:1559-63

[85] Sun J,Zhang S,Li Z.Long non-coding RNAs: critical players in hepatocellular carcinoma.Int J Mol Sci2014;15:20434-48 PMCID:PMC4264176

[86] Zhu X,Zhou J.Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression.Biochem Biophys Res Commun2016;469:319-25

[87] Xu H,Chen Y.Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma.Clin Chem Lab Med2018;56:479-84

[88] Zhang J,Zhao Q,Li X.A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic biomarker in hepatocellular carcinoma. .Cancer Med2018;

[89] Imamura H,Tanaka E,Hasegawa K.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003;38:200-7

[90] Xu W,Chen L,Zhang XF.Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy.Clin Cancer Res2011;17:3783-93

[91] Fan JL,Yuan CH,Wang FB.Circulating tumor cells for predicting the prognostic of patients with hepatocellular carcinoma: a meta analysis.Cell Physiol Biochem2015;37:629-40

[92] Sun C,Deng Z,Feng Q.The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma: a meta-analysis.Medicine (Baltimore)2017;

[93] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50

[94] Swystun LL,Liaw PC.Breast cancer chemotherapy induces the release of cell-free dna, a novel procoagulant stimulus.J Thromb Haemost2011;9:2313-21

[95] García-Olmo DC,García-Arranz M,Stroun M.Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells.Cancer Res2010;70:560-7

[96] Kirk GD,Mendy M,Whittle H.249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.Oncogene2005;24:5858-67

[97] Liao W,Ge P,Xu H.Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis.Medicine (Baltimore)2015;

[98] Shi M,Sekar K,Ooi LL.A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma.Eur J Cancer2014;50:928-36

[99] Hann HW,Park G,Song W.Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.Hepatoma Res2017;3:105-11 PMCID:PMC5546802

[100] Luo P,Hua R,Li Z.A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.Hepatology2017;

[101] Yin H,Wu J,Shedden KA.Mass-selected site-specific core-fucosylation of serum proteins in hepatocellular carcinoma.J Proteome Res2015;14:4876-84 PMCID:PMC4636958

[102] Gray J,Beale GS,Miele L.A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.BMC Cancer2009;9:271 PMCID:PMC2729079

[103] Zinkin NT,Bhaskar K,Spentzos D.Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.Clin Cancer Res2008;14:470-7

[104] Nahon P.Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis.J Hepatol2012;57:663-74

[105] Walker AJ,Pedergnana V,Irving WL.Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review.J Viral Hepat2018;25:442-56

[106] Hoshida Y,Sangiovanni A,Hur C.Prognostic gene-expression signature for patients with hepatitis C-related early-stage cirrhosis.Gastroenterology2013;144:1024-30 PMCID:PMC3633736

[107] Llovet JM,Pikarsky E,Schwartz M.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[108] Llovet JM,Wurmbach E,Fiel MI.A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.Gastroenterology2006;131:1758-67

[109] Han X,Sun Y.Circulating tumor DNA as biomarkers for cancer detection.Genomics Proteomics Bioinformatics2017;15:59-72 PMCID:PMC5414889

[110] Cabel L,Buecher B,Bidard FC.Circulating tumor DNA detection in hepatocellular carcinoma.Ann Oncol2018;29:1094-6

[111] Nault JC,Villanueva A,Rebouissou S.A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.Gastroenterology2013;145:176-87

[112] Villa E,Lei B,Cammà C.Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. .Gut2016;65:861-9

[113] Hoshida Y,Kobayashi M,Chiang DY.Gene expression in fixed tissues and outcome in hepatocellular carcinoma.N Engl J Med2008;359:1995-2004 PMCID:PMC2963075

[114] Arao T,Matsumoto K,Kimura H.FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.Hepatology2013;57:1407-15

[115] Bruix J,Meinhardt G,De Sanctis Y.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies.J Hepatol2017;67:999-1008

[116] Llovet JM,Lachenmayer A.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat Rev Clin Oncol2015;12:408-24

[117] Llovet JM,Lathia CD,Meinhardt G.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res2012;18:2290-300

[118] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet2017;389:56-66

[119] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[120] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63

[121] Zhu AX,Yen CJ,Galle PR.REACH-2: a randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe.J Clin Oncol2018;36:4003

[122] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502

[123] Maleki Vareki S,Duran I.Biomarkers of response to PD-1/PD-L1 inhibition.Crit Rev Oncol Hematol2017;116:116-24

[124] Sia D,Martinez-Quetglas I,Villacorta-Martin C.Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features.Gastroenterology2017;153:812-26

[125] Wang L,Pan LH,Yao DF.Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int2015;14:361-6

[126] Filmus J.Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.FEBS J2013;280:2471-6

[127] Fu X,Zheng B,Wang C.KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma.Int J Oncol2018;

[128] Hann HW,Lai Y,Myers RE.Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.J Gastroenterol Hepatol2015;30:131-8 PMCID:PMC4418451

[129] Tang T,Li GW,Li Y.Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients.Clin Radiol2018;73:259-65

[130] Suh B,Shin DW,Yang HK.High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.Hepatology2015;61:1261-8

[131] Demir M,Lang S,Bowe A.Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients.Medicine (Baltimore)2016;

[132] Toyoda H,Tachi Y,Yasuda S.Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.Antivir Ther2017;22:185-93

[133] Choi WM,Ahn H,Cho YY.Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.Liver Int2015;35:1992-2000